Trends in utilization and dosing of antipsychotic drugs in Scandinavia: comparison of 2006 and 2016

Mikkel Højlund*, Anton Pottegård, Erik Johnsen, Rune A. Kroken, Johan Reutfors, Povl Munk-Jørgensen, Christoph U. Correll

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Aims: The aim of this study was to investigate time trends in dosing and prevalence of antipsychotic prescriptions in Scandinavia. Methods: We retrieved data on antipsychotic use between 2006 and 2016 from Danish, Norwegian and Swedish national prescription registers. For each antipsychotic, we calculated prevalence of use and mean doses, overall and for specific age groups (young, adults and elderly). Results: Antipsychotic use in Scandinavia increased from 16.5 to 17.2 users/1000 inhabitants between 2006 and 2016 (+2.4%, annual change: 0.07 users/1000 inhabitants/year, 95% CI: 0.02–0.20, P = 0.02). In 2006, chlorprothixene and levomepromazine were the most commonly used antipsychotics. By 2016, quetiapine was the most used antipsychotic in all three countries and across all age groups, with an overall 1-year prevalence of 4.05–9.97 users/1000 inhabitants (annual change: 0.57 users/1000 inhabitants/year, 95% CI: 0.54–0.60, P < 0.001). Quetiapine showed a marked decrease in mean doses during the 11-year study period (0.46–0.28 defined daily doses (DDD)/user/day: 39.1%, −0.02 DDD/user/day/year, 95% CI: −0.020 to −0.015, P < 0.001). In 2016, the highest mean doses were seen for clozapine (0.90–1.07 DDD/user/day) and olanzapine (0.66–0.88 DDD/user/day). Conclusions: There is an increased prevalence of antipsychotic prescriptions that coincides with low and/or decreasing mean doses of the majority of commonly used antipsychotics in Scandinavia. Of all antipsychotics, this development was most pronounced for quetiapine. Reasons for and consequences of increased antipsychotic use that lasts shorter periods of time requires further study.

OriginalsprogEngelsk
TidsskriftBritish Journal of Clinical Pharmacology
Vol/bind85
Udgave nummer7
Sider (fra-til)1598-1606
ISSN0306-5251
DOI
StatusUdgivet - jul. 2019

Fingeraftryk

Scandinavian and Nordic Countries
Prescriptions
Chlorprothixene
Age Groups
Methotrimeprazine
Clozapine
Young Adult

Citer dette

Højlund, Mikkel ; Pottegård, Anton ; Johnsen, Erik ; Kroken, Rune A. ; Reutfors, Johan ; Munk-Jørgensen, Povl ; Correll, Christoph U. / Trends in utilization and dosing of antipsychotic drugs in Scandinavia : comparison of 2006 and 2016. I: British Journal of Clinical Pharmacology. 2019 ; Bind 85, Nr. 7. s. 1598-1606.
@article{c4365ae2a076449388e544784f97bde3,
title = "Trends in utilization and dosing of antipsychotic drugs in Scandinavia: comparison of 2006 and 2016",
abstract = "Aims: The aim of this study was to investigate time trends in dosing and prevalence of antipsychotic prescriptions in Scandinavia. Methods: We retrieved data on antipsychotic use between 2006 and 2016 from Danish, Norwegian and Swedish national prescription registers. For each antipsychotic, we calculated prevalence of use and mean doses, overall and for specific age groups (young, adults and elderly). Results: Antipsychotic use in Scandinavia increased from 16.5 to 17.2 users/1000 inhabitants between 2006 and 2016 (+2.4{\%}, annual change: 0.07 users/1000 inhabitants/year, 95{\%} CI: 0.02–0.20, P = 0.02). In 2006, chlorprothixene and levomepromazine were the most commonly used antipsychotics. By 2016, quetiapine was the most used antipsychotic in all three countries and across all age groups, with an overall 1-year prevalence of 4.05–9.97 users/1000 inhabitants (annual change: 0.57 users/1000 inhabitants/year, 95{\%} CI: 0.54–0.60, P < 0.001). Quetiapine showed a marked decrease in mean doses during the 11-year study period (0.46–0.28 defined daily doses (DDD)/user/day: 39.1{\%}, −0.02 DDD/user/day/year, 95{\%} CI: −0.020 to −0.015, P < 0.001). In 2016, the highest mean doses were seen for clozapine (0.90–1.07 DDD/user/day) and olanzapine (0.66–0.88 DDD/user/day). Conclusions: There is an increased prevalence of antipsychotic prescriptions that coincides with low and/or decreasing mean doses of the majority of commonly used antipsychotics in Scandinavia. Of all antipsychotics, this development was most pronounced for quetiapine. Reasons for and consequences of increased antipsychotic use that lasts shorter periods of time requires further study.",
keywords = "antipsychotics, drug utilization, pharmacoepidemiology, psychopharmacology",
author = "Mikkel H{\o}jlund and Anton Potteg{\aa}rd and Erik Johnsen and Kroken, {Rune A.} and Johan Reutfors and Povl Munk-J{\o}rgensen and Correll, {Christoph U.}",
year = "2019",
month = "7",
doi = "10.1111/bcp.13945",
language = "English",
volume = "85",
pages = "1598--1606",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "7",

}

Trends in utilization and dosing of antipsychotic drugs in Scandinavia : comparison of 2006 and 2016. / Højlund, Mikkel; Pottegård, Anton; Johnsen, Erik; Kroken, Rune A.; Reutfors, Johan; Munk-Jørgensen, Povl; Correll, Christoph U.

I: British Journal of Clinical Pharmacology, Bind 85, Nr. 7, 07.2019, s. 1598-1606.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Trends in utilization and dosing of antipsychotic drugs in Scandinavia

T2 - comparison of 2006 and 2016

AU - Højlund, Mikkel

AU - Pottegård, Anton

AU - Johnsen, Erik

AU - Kroken, Rune A.

AU - Reutfors, Johan

AU - Munk-Jørgensen, Povl

AU - Correll, Christoph U.

PY - 2019/7

Y1 - 2019/7

N2 - Aims: The aim of this study was to investigate time trends in dosing and prevalence of antipsychotic prescriptions in Scandinavia. Methods: We retrieved data on antipsychotic use between 2006 and 2016 from Danish, Norwegian and Swedish national prescription registers. For each antipsychotic, we calculated prevalence of use and mean doses, overall and for specific age groups (young, adults and elderly). Results: Antipsychotic use in Scandinavia increased from 16.5 to 17.2 users/1000 inhabitants between 2006 and 2016 (+2.4%, annual change: 0.07 users/1000 inhabitants/year, 95% CI: 0.02–0.20, P = 0.02). In 2006, chlorprothixene and levomepromazine were the most commonly used antipsychotics. By 2016, quetiapine was the most used antipsychotic in all three countries and across all age groups, with an overall 1-year prevalence of 4.05–9.97 users/1000 inhabitants (annual change: 0.57 users/1000 inhabitants/year, 95% CI: 0.54–0.60, P < 0.001). Quetiapine showed a marked decrease in mean doses during the 11-year study period (0.46–0.28 defined daily doses (DDD)/user/day: 39.1%, −0.02 DDD/user/day/year, 95% CI: −0.020 to −0.015, P < 0.001). In 2016, the highest mean doses were seen for clozapine (0.90–1.07 DDD/user/day) and olanzapine (0.66–0.88 DDD/user/day). Conclusions: There is an increased prevalence of antipsychotic prescriptions that coincides with low and/or decreasing mean doses of the majority of commonly used antipsychotics in Scandinavia. Of all antipsychotics, this development was most pronounced for quetiapine. Reasons for and consequences of increased antipsychotic use that lasts shorter periods of time requires further study.

AB - Aims: The aim of this study was to investigate time trends in dosing and prevalence of antipsychotic prescriptions in Scandinavia. Methods: We retrieved data on antipsychotic use between 2006 and 2016 from Danish, Norwegian and Swedish national prescription registers. For each antipsychotic, we calculated prevalence of use and mean doses, overall and for specific age groups (young, adults and elderly). Results: Antipsychotic use in Scandinavia increased from 16.5 to 17.2 users/1000 inhabitants between 2006 and 2016 (+2.4%, annual change: 0.07 users/1000 inhabitants/year, 95% CI: 0.02–0.20, P = 0.02). In 2006, chlorprothixene and levomepromazine were the most commonly used antipsychotics. By 2016, quetiapine was the most used antipsychotic in all three countries and across all age groups, with an overall 1-year prevalence of 4.05–9.97 users/1000 inhabitants (annual change: 0.57 users/1000 inhabitants/year, 95% CI: 0.54–0.60, P < 0.001). Quetiapine showed a marked decrease in mean doses during the 11-year study period (0.46–0.28 defined daily doses (DDD)/user/day: 39.1%, −0.02 DDD/user/day/year, 95% CI: −0.020 to −0.015, P < 0.001). In 2016, the highest mean doses were seen for clozapine (0.90–1.07 DDD/user/day) and olanzapine (0.66–0.88 DDD/user/day). Conclusions: There is an increased prevalence of antipsychotic prescriptions that coincides with low and/or decreasing mean doses of the majority of commonly used antipsychotics in Scandinavia. Of all antipsychotics, this development was most pronounced for quetiapine. Reasons for and consequences of increased antipsychotic use that lasts shorter periods of time requires further study.

KW - antipsychotics

KW - drug utilization

KW - pharmacoepidemiology

KW - psychopharmacology

U2 - 10.1111/bcp.13945

DO - 10.1111/bcp.13945

M3 - Journal article

C2 - 30927284

VL - 85

SP - 1598

EP - 1606

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 7

ER -